Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Chief Business Officer | February 16, 2023 | February 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2033-02-15 | Direct | 97,900 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 97,900 · Balance 97,900 F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 21, 2023 17:03 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 97,900 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-23-011270 · doc4.xml · derivative · entry 1 NASSHORN PATRICIA · CIK 0001251374 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,900 Underlying: Common Stock · 97,900 shares Expires 2033-02-15 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 17:22 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021502 · doc4.xml · derivative · entry 1 NASSHORN PATRICIA · CIK 0001251374 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| December 15, 2021 Filed Jan 4, 2022 17:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0000899243-22-000537 · doc4.xml · derivative · entry 1 NASSHORN PATRICIA · CIK 0001251374 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-15 F1 · derivative.exercise_date: This stock option grant becomes exercisable in four equal semi-annual installments beginning on June 15, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.